Best Practice & Research Clinical Obstetrics & Gynaecology
Volume 24, Issue 3 , Pages 277-287 , June 2010

Pharmacogenetic influences in obstetric anaesthesia

  • Ruth Landau, MD (Virginia and Prentice Bloedel Professor of Anesthesiology, Director of Obstetric Anesthesia and Clinical Genetics Research)

      Affiliations

    • Corresponding Author InformationTel.: +1 206 543 2187; Fax: +1 206 543 2958.

References 

  1. Kalow W, Gunn DR. The relation between dose of succinylcholine and duration of apnea in man. J Pharmacol Exp Ther. 1957;120:203–214
  2. Allen PD. Anesthesia and the human genome project: the quest for accurate prediction of drug responses. Anesthesiology. 2005;102:494–495
  3. Eisenach JH, Schroeder DR. Genomic discoveries in perioperative medicine: educating the audience. Anesthesiology. 2009;110:693–695
  4. Galley HF, Mahdy A, Lowes DA. Pharmacogenetics and anesthesiologists. Pharmacogenomics. 2005;6:849–856
  5. Iohom G, Fitzgerald D, Cunningham AJ. Principles of pharmacogenetics–implications for the anaesthetist. Br J Anaesth. 2004;93:440–450
  6. Iravani M. Anesthesia and pharmacogenetics. Am J Ther. 2009;16:313–315
  7. Kim JH, Schwinn DA, Landau R. Pharmacogenomics and perioperative medicine–implications for modern clinical practice. Can J Anaesth. 2008;55:799–806
  8. Palmer SN, Giesecke NM, Body SC, et al. Pharmacogenetics of anesthetic and analgesic agents. Anesthesiology. 2005;102:663–671
  9. Searle R, Hopkins PM. Pharmacogenomic variability and anaesthesia. Br J Anaesth. 2009;103:14–25
  10. Schwinn DA, Podgoreanu M. Pharmacogenomics and end-organ susceptibility to injury in the perioperative period. Best Pract Res Clin Anaesthesiol. 2008;22:23–37
  11. Ngan Kee WD, Khaw KS. Vasopressors in obstetrics: what should we be using?. Curr Opin Anaesthesiol. 2006;19:238–243
  12. Liggett SB. Polymorphisms of the β2-adrenergic receptor. N Engl J Med. 2002;346:536–538
  13. Smiley RM, Blouin JL, Negron M, et al. β2-adrenoceptor genotype affects vasopressor requirements during spinal anesthesia for cesarean delivery. Anesthesiology. 2006;104:644–650
  14. Aya AG, Mangin R, Vialles N, et al. Patients with severe preeclampsia experience less hypotension during spinal anesthesia for elective cesarean delivery than healthy parturients: a prospective cohort comparison. Anesth Analg. 2003;97:867–872
  15. Aya AG, Vialles N, Tanoubi I, et al. Spinal anesthesia-induced hypotension: a risk comparison between patients with severe preeclampsia and healthy women undergoing preterm cesarean delivery. Anesth Analg. 2005;101:869–875
  16. Ramanathan J, Ramsay R, Blouin J, et al. β2adrenoceptor haplotypes and vasopressor response during spinal anesthesia for cesarean section in preeclampsia. ASA Abstract. 2009;A860
  17. Cooper DW, Carpenter M, Mowbray P, et al. Fetal and maternal effects of phenylephrine and ephedrine during spinal anesthesia for cesarean delivery. Anesthesiology. 2002;97:1582–1590
  18. Ngan Kee WD, Khaw KS, Tan PE, et al. Placental transfer and fetal metabolic effects of phenylephrine and ephedrine during spinal anesthesia for cesarean delivery. Anesthesiology. 2009;111:506–512
  19. Lanfear DE, Jones PG, Marsh S, et al. β2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA. 2005;294:1526–1533
  20. Sofowora GG, Dishy V, Muszkat M, et al. A common β1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to β-blockade. Clin Pharmacol Ther. 2003;73:366–371
  21. Brodde OE, Stein CM. The Gly389Arg β1-adrenergic receptor polymorphism: a predictor of response to beta-blocker treatment?. Clin Pharmacol Ther. 2003;74:299–302
  22. Pacanowski MA, Gong Y, Cooper-Dehoff RM, et al. β-adrenergic receptor gene polymorphisms and β-blocker treatment outcomes in hypertension. Clin Pharmacol Ther. 2008;84:715–721
  23. Xie HG, Dishy V, Sofowora G, et al. Arg389Gly β1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. Pharmacogenetics. 2001;11:191–197
  24. Kurnik D, Li C, Sofowora GG, et al. β1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade. Pharmacogenet Genomics. 2008;18:895–902
  25. Cresci S, Kelly RJ, Cappola TP, et al. Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol. 2009;54:432–444
  26. Pereira NL, Weinshilboum RM. Cardiovascular pharmacogenomics and individualized drug therapy. Nat Rev Cardiol. 2009;6:632–638
  27. Contopoulos-Ioannidis DG, Manoli EN, Ioannidis JP. Meta-analysis of the association of β2-adrenergic receptor polymorphisms with asthma phenotypes. J Allergy Clin Immunol. 2005;115:963–972
  28. Lima JJ, Thomason DB, Mohamed MH, et al. Impact of genetic polymorphisms of the β2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther. 1999;65:519–525
  29. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet. 2004;364:1505–1512
  30. Wechsler ME, Lehman E, Lazarus SC, et al. β-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2006;173:519–526
  31. Lima JJ, Blake KV, Tantisira KG, et al. Pharmacogenetics of asthma. Curr Opin Pulm Med. 2009;15:57–62
  32. Landau R, Xie HG, Dishy V, et al. β2-Adrenergic receptor genotype and preterm delivery. Am J Obstet Gynecol. 2002;187:1294–1298
  33. Ozkur M, Dogulu F, Ozkur A, et al. Association of the Gln27Glu polymorphism of the β2-adrenergic receptor with preterm labor. Int J Gynaecol Obstet. 2002;77:209–215
  34. Doh K, Sziller I, Vardhana S, et al. β2-adrenergic receptor gene polymorphisms and pregnancy outcome. J Perinat Med. 2004;32:413–417
  35. Landau R, Morales MA, Antonarakis SE, et al. Arg16 homozygosity of the β2-adrenergic receptor improves the outcome after β2-agonist tocolysis for preterm labor. Clin Pharmacol Ther. 2005;78:656–663
  36. Esplin MS, Varner MW. Genetic factors in preterm birth–the future. BJOG. 2005;112(Suppl. 1):97–102
  37. Romero R, Espinoza J, Rogers WT, et al. Proteomic analysis of amniotic fluid to identify women with preterm labor and intra-amniotic inflammation/infection: the use of a novel computational method to analyze mass spectrometric profiling. J Matern Fetal Neonatal Med. 2008;21:367–388
  38. Buhimschi CS, Rosenberg VA, Dulay AT, et al. Multidimensional system biology: genetic markers and proteomic biomarkers of adverse pregnancy outcome in preterm birth. Am J Perinatol. 2008;25:175–187
  39. Foulkes T, Wood JN. Pain genes. PLoS Genet. 2008;4:e1000086
  40. Lacroix-Fralish ML, Ledoux JB, Mogil JS. The Pain genes database: an interactive web browser of pain-related transgenic knockout studies. Pain. 2007;131(3):e1–e4
  41. Cox JJ, Reimann F, Nicholas AK, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature. 2006;444:894–898
  42. Goldberg YP, MacFarlane J, MacDonald ML, et al. Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet. 2007;71:311–319
  43. Nilsen KB, Nicholas AK, Woods CG, et al. Two novel SCN9A mutations causing insensitivity to pain. Pain. 2009;143:155–158
  44. de Leon J, Susce MT, Murray-Carmichael E. The amplichip cyp450 genotyping test: integrating a new clinical tool. Mol Diagn Ther. 2006;10:135–151
  45. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004;351:2827–2831
  46. Koren G, Cairns J, Chitayat D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet. 2006;368:704
  47. Berlin CM, Paul IM, Vesell ES. Safety issues of maternal drug therapy during breastfeeding. Clin Pharmacol Ther. 2009;85:20–22
  48. Madadi P, Koren G. Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. Pharmacogenomics. 2008;9:1267–1284
  49. Madadi P, Ross CJ, Hayden MR, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther. 2009;85:31–35
  50. Willmann S, Edginton AN, Coboeken K, et al. Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study. Clin Pharmacol Ther. 2009;
  51. Ciszkowski C, Madadi P, Phillips MS, et al. Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med. 2009;361:827–828
  52. Madadi P, Koren G, Cairns J, et al. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician. 2007;53:33–35
  53. Stamer UM, Stuber F. Codeine and tramadol analgesic efficacy and respiratory effects are influenced by CYP2D6 genotype. 1294-5; author reply Anaesthesia. 2007;62:1295–1296
  54. Stamer UM, Stuber F, Muders T, et al. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth Analg. 2008;107:926–929
  55. Landau R, Cahana A, Smiley RM, et al. Genetic variability of μ-opioid receptor in an obstetric population. Anesthesiology. 2004;100:1030–1033
  56. Tan EC, Tan CH, Karupathivan U, et al. μ-opioid receptor gene polymorphisms and heroin dependence in Asian populations. Neuroreport. 2003;14:569–572
  57. Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human μ-opioid receptor gene alters β-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A. 1998;95:9608–9613
  58. Fillingim RB, Kaplan L, Staud R, et al. The A118G single nucleotide polymorphism of the μ-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J Pain. 2005;6:159–167
  59. Klepstad P, Rakvag TT, Kaasa S, et al. The 118 A > G polymorphism in the human μ-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand. 2004;48:1232–1239
  60. Reyes-Gibby CC, Shete S, Rakvag T, et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain. 2007;130:25–30
  61. Ginosar Y, Davidson EM, Meroz Y, et al. μ-opioid receptor (A118G) single-nucleotide polymorphism affects alfentanil requirements for extracorporeal shock wave lithotripsy: a pharmacokinetic-pharmacodynamic study. Br J Anaesth. 2009;103:420–427
  62. Chou WY, Wang CH, Liu PH, et al. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology. 2006;105:334–337
  63. Chou WY, Yang LC, Lu HF, et al. Association of μ-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand. 2006;50:787–792
  64. Coulbault L, Beaussier M, Verstuyft C, et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther. 2006;79:316–324
  65. Hayashida M, Nagashima M, Satoh Y, et al. Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics. 2008;9:1605–1616
  66. Lotsch J. Basic genetic statistics are necessary in studies of functional associations in anesthesiology. Anesthesiology. 2007;107:168–169
  67. Lotsch J, Zimmermann M, Darimont J, et al. Does the A118G polymorphism at the μ-opioid receptor gene protect against morphine-6-glucuronide toxicity?. Anesthesiology. 2002;97:814–819
  68. Oertel BG, Schmidt R, Schneider A, et al. The μ-opioid receptor gene polymorphism 118A > G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics. 2006;16:625–636
  69. Romberg RR, Olofsen E, Bijl H, et al. Polymorphism of μ-opioid receptor gene (OPRM1:c.118A > G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology. 2005;102:522–530
  70. Landau R, Kern C, Columb MO, et al. Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women. Pain. 2008 Sep 30;139(1):5–14
  71. Walter C, Lotsch J. Meta-analysis of the relevance of the OPRM1 118A > G genetic variant for pain treatment. Pain. 2009;
  72. Wong C, McCarthy R, Blouin JL, et al. μ-Opioid receptor genetic polymorphism and the duration of intrathecal fentanyl labor analgesia. Abstract SOAP. 2007;A26
  73. Wong C, Ebarvia M, Blouin J, et al. influence of μ-opioid receptor genetic polymorphism on postoperative intrathecal morphine analgesia. ASA Abstract. 2008;A620
  74. Sia AT, Lim Y, Lim EC, et al. A118G single nucleotide polymorphism of human μ-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology. 2008;109:520–526
  75. Tan EC, Lim EC, Teo YY, et al. Ethnicity and OPRM variant independently predict pain perception and patient-controlled analgesia usage for post-operative pain. Mol Pain. 2009;5:32
  76. Nielsen CS, Stubhaug A, Price DD, et al. Individual differences in pain sensitivity: Genetic and environmental contributions. Pain. 2007;
  77. Zubieta JK, Heitzeg MM, Smith YR, et al. COMT val158met genotype affects μ-opioid neurotransmitter responses to a pain stressor. Science. 2003;299:1240–1243
  78. Kim H, Neubert JK, San Miguel A, et al. Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain. 2004;109:488–496
  79. Diatchenko L, Slade GD, Nackley AG, et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet. 2005;14:135–143
  80. Diatchenko L, Nackley AG, Slade GD, et al. Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain. 2006;125:216–224
  81. Flood P, Evans J, Connel-Price J. polymorphisms in the beta2-adrenergic receptor are associated with a more rapid, less painful labor. ASA Abstract. 2008;A619
  82. Kim H, Clark D, Dionne RA. Genetic contributions to clinical pain and analgesia: avoiding pitfalls in genetic research. J Pain. 2009;10:663–693
  83. Stamer UM, Stuber F. The pharmacogenetics of analgesia. Expert Opin Pharmacother. 2007;8:2235–2245
  84. Kosarac B, Fox AA, Collard CD. Effect of genetic factors on opioid action. Curr Opin Anaesthesiol. 2009;22:476–482
  85. Lacroix-Fralish ML, Mogil JS. Progress in genetic studies of pain and analgesia. Annu Rev Pharmacol Toxicol. 2009;49:97–121
  86. Mogil JS. Are we getting anywhere in human pain genetics?. Pain. 2009;
  87. Kim H, Ramsay E, Lee H, et al. Genome-wide association study of acute post-surgical pain in humans. Pharmacogenomics. 2009;10:171–179
  88. Mata M, Fink DJ. Gene therapy for pain. Anesthesiology. 2007;106:1079–1080
  89. Mata M, Hao S, Fink DJ. Applications of gene therapy to the treatment of chronic pain. Curr Gene Ther. 2008;8:42–48
  90. Dib-Hajj SD, Binshtok AM, Cummins TR, et al. Voltage-gated sodium channels in pain states: role in pathophysiology and targets for treatment. Brain Res Rev. 2009;60:65–83
  91. Wang L, Weinshilboum RM. Pharmacogenomics: candidate gene identification, functional validation and mechanisms. Hum Mol Genet. 2008;17:R174–R179
  92. Flockhart DA, Skaar T, Berlin DS, et al. Clinically available pharmacogenomics tests. Clin Pharmacol Ther. 2009;86:109–113

PII: S1521-6934(09)00147-3

doi: 10.1016/j.bpobgyn.2009.11.009

Best Practice & Research Clinical Obstetrics & Gynaecology
Volume 24, Issue 3 , Pages 277-287 , June 2010

Article Tools